The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis

2015 ACR/ARHP Annual Meeting: Latest Clinical Literature Offers New Strategies in Lupus Nephritis

March 15, 2016 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF
iomis/shutterstock.com

iomis/shutterstock.com

SAN FRANCISCO—Rheumatologists have to look no further than the American College of Rheumatology guidelines to know that the options for patients with lupus nephritis are sometimes not very appealing.

You Might Also Like
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
  • 2014 ACR/ARHP Annual Meeting: Predicting Outcomes for Patients with Lupus Nephritis
  • 2015 ACR/ARHP Annual Meeting: Research Offers Clues to Environmental Triggers of RA
Explore This Issue
March 2016
Also By This Author
  • Progress Slow in Development of Useful Biomarkers for Rheumatoid Arthritis Treatment

The first-line choices are either mycophenolate mofetil (MMF) plus glucocorticoids or cyclophosphamide (CYC), also with glucocorticoids—and all of their attendant side effects. The problem: evidence, said Joan Merrill, MD, chair of the Clinical Pharmacology Research Program at the Oklahoma Medical Research Foundation. Her work focuses on lupus and she was one of the contributors to the guidelines. The work was presented to attendees of the 2015 ACR/ARHP Annual Meeting.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Our task was to make recommendations based on the best evidence,” Dr. Merrill said. “And the problem here is that we don’t have sufficient evidence yet to do what our technology has now made possible, which is to approach this disease in a much more rational way.”

The limited recommendations have left clinicians foraging for guidance—tidbits and nuances that can be gleaned from the literature to help them find something that works, especially for their harder-to-treat patients.

Dr. Merrill

Dr. Merrill

Dr. Merrill drew a comparison between lupus nephritis treatment and mixed martial arts (MMA), disclosing that she is the mother of an MMA fighter.

“In MMA, you are going into the octagon to fight some of the most lethal fighters in the world, and you cannot be a one-trick pony—you’ve got to know how to box, you’ve got to know how to kickbox, and you’ve got to know how to roll around on the ground and strangle people,” she said. “And I think that’s a very good analogy for what we’re facing, because lupus nephritis is a formidable opponent.”

MMF vs. CYC

There have been only three rigorous induction trials directly comparing MMF with CYC—and only one of them, a 140-patient trial in 2005, found that MMF was superior.1 Another study, an international trial involving 370 patients, discouragingly found that the six-month response rates for both drugs were not much higher than 50%.2

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“This means that we have a slightly under 50% chance of progressing to significant kidney damage,” Dr. Merrill pointed out.

She also noted that the trial in which MMF was found to be superior to CYC had a much higher percentage of African-American subjects, who have been found in other studies to do worse on cyclophosphamide.

But beyond this starting point, other treatment options and strategies are emerging in the literature, if only in morsels, Dr. Merrill suggested.

Tacrolimus

A randomized study in 2014 out of Hong Kong, involving 150 patients, found that tacrolimus and MMF were essentially equivalent as induction therapy in lupus nephritis. Patients were Class III through V.3 This might offer some guidance in the absence of other options, Dr. Merrill said. There were more flares with tacrolimus in the maintenance period, but the difference was not found to be significant.

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports, SLE (Lupus) Tagged With: 2015 ACR/ARHP Annual Meeting, American College of Rheumatology, Clinical, Guidelines, Lupus nephritis, recommendations, Research, studiesIssue: March 2016

You Might Also Like:
  • 2014 ACR/ARHP Annual Meeting: Lupus Nephritis
  • 2014 ACR/ARHP Annual Meeting: Predicting Outcomes for Patients with Lupus Nephritis
  • 2015 ACR/ARHP Annual Meeting: Research Offers Clues to Environmental Triggers of RA
  • The ACR’s State-of-the-Art Clinical Symposium: Experts Discuss Jakinibs, Osteoarthritis, Membranous Lupus Nephritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)